{"title":"Identification of novel RASGRP2 mutations in patients with platelet dysfunction","authors":"Mohadese Heydarali Broojerdi , Shadi Tabibian , Rima Manafi Shabestari , Mahmood Barati , Mehrnoosh Shanaki , Majid Safa","doi":"10.1016/j.transci.2025.104202","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Inherited platelet function disorders (IPFDs) are rare hereditary diseases characterized by dysregulation of genes related to platelet receptors expression or signal transduction pathways. Bleeding disorder platelet-type 18 (BDPLT18) is an infrequent autosomal recessive platelet function disorder caused by <em>RASGRP2</em> mutation. The <em>RASGRP2</em> gene encodes calcium- and DAG-regulated guanine exchange factor-1 (CalDAG-GEFI), which plays a role in the activation of the αIIbβ3 integrin in platelets. In present study, eleven unrelated patients were examined for mutational analysis to identify mutations in <em>RASGRP2</em> gene that may lead to BDPLT18<strong>.</strong></div></div><div><h3>Methods</h3><div>The study included 11 unrelated cases (6 males and 5 females) with various bleeding disorders in 2024. The patients were selected based on normal expression of CD41, CD61, and CD42b, as well as an impaired response to ADP, collagen, and arachidonic acid. The plasma coagulation parameters of the patients were normal. Polymerase chain reaction (PCR) and sanger sequencing were used to screen for mutations in the <em>RASGRP2</em> gene.</div></div><div><h3>Results</h3><div>A total of 7 mutations were identified in the patients. Including four novel missense mutations (<em>RASGRP2</em>: p.F497L, p.F501L, p.N505K, p.C515G) and 3 known mutations (<em>RASGRP2</em>: p.D441N, p.R494Afs*54, g.10410 G>T). These mutations are predicted to cause disease and alter the characteristics of the CalDAG-GEFI protein.</div></div><div><h3>Conclusion</h3><div>Identifying <em>RASGRP2</em> gene mutations and their association with bleeding episodes is crucial for confirming the diagnosis of BDPLT18, distinguishing it from other platelet disorders, and using effective therapeutics to prevent bleeding abnormalities.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104202"},"PeriodicalIF":1.2000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion and Apheresis Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1473050225001405","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Inherited platelet function disorders (IPFDs) are rare hereditary diseases characterized by dysregulation of genes related to platelet receptors expression or signal transduction pathways. Bleeding disorder platelet-type 18 (BDPLT18) is an infrequent autosomal recessive platelet function disorder caused by RASGRP2 mutation. The RASGRP2 gene encodes calcium- and DAG-regulated guanine exchange factor-1 (CalDAG-GEFI), which plays a role in the activation of the αIIbβ3 integrin in platelets. In present study, eleven unrelated patients were examined for mutational analysis to identify mutations in RASGRP2 gene that may lead to BDPLT18.
Methods
The study included 11 unrelated cases (6 males and 5 females) with various bleeding disorders in 2024. The patients were selected based on normal expression of CD41, CD61, and CD42b, as well as an impaired response to ADP, collagen, and arachidonic acid. The plasma coagulation parameters of the patients were normal. Polymerase chain reaction (PCR) and sanger sequencing were used to screen for mutations in the RASGRP2 gene.
Results
A total of 7 mutations were identified in the patients. Including four novel missense mutations (RASGRP2: p.F497L, p.F501L, p.N505K, p.C515G) and 3 known mutations (RASGRP2: p.D441N, p.R494Afs*54, g.10410 G>T). These mutations are predicted to cause disease and alter the characteristics of the CalDAG-GEFI protein.
Conclusion
Identifying RASGRP2 gene mutations and their association with bleeding episodes is crucial for confirming the diagnosis of BDPLT18, distinguishing it from other platelet disorders, and using effective therapeutics to prevent bleeding abnormalities.
期刊介绍:
Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues.
Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.